News
A new tool for processing single cell RNA-sequencing data
Single-cell RNA-sequencing is a genomic approach for the detection and quantitative analysis of RNA molecules in biological samples and has been extremely successful in the past few years in studying the cell-composition of biological samples, exploring cell proliferation and cell migration mechanisms and providing another layer of information in addition to bulk-RNA sequencing technologies.The new… Continue reading→
Mass Spectrometry Proteomics Data : From raw data to discovery
October 7, 2021 (7:00 PM – 8:00 PM EEST) Introduction to experimental and computational mass spectrometry proteomics pipelines for biomecial application and discovery of biomarkers. Mass spectrometry-based proteomics is a strong tool for the proteome of biosamples and has numerous applications for the discovery of diagnostic, prognostic and therapeutic biomarkers. However, there exist several different… Continue reading→
Optimized and automatized biomarker discovery and processing of biomedical data with InSyBio Pipelines
The new version of InSyBio Suite includes InSyBio Pipelines, a new tool for automatizing and optimizing the computational process for identifying biomarkers. The CEO of InSyBio, Labros Digonis, stated that “This new version of InSyBio Suite overcomes some major limitations of biomedical big data analytics and biomarker discovery and opens the road to establish it as the… Continue reading→
Personalizing the treatment of Chronic Pain Patients using the Salonpas® Pain Relieving Patch and Interpretable Artificial Intelligence
Traditionally, prescribed opioid analgesics for treating Chronic Pain can become harmful for the patients and negatively affect their lives. In the meantime, the Chronic Pain condition is affecting the lives of millions of patients deteriorating their ability to perform everyday tasks, diminishing their performance in their work environment and, in general, reducing their satisfaction of… Continue reading→
InSyBio joins Loyal VC program and receives initial investment
InSyBio has joined the Loyal VC program which includes an initial investment from the Toronto, Canada based international fund and provides InSyBio with access to Loyal VC’s global network of over 400 advisors and experienced entrepreneurs, accelerator leaders, advisors, angels and venture investors. InSyBio will benefit from active business development support and guidance as well as having… Continue reading→
Precision Chronic Pain Treatment Tool: a first-of-its-kind tool for personalizing treatment of Chronic Pain Patients
In an effort to find a better alternative to the traditionally prescribed opioid analgesics, InSyBio worked in collaboration with Clarity Science LLC and developed a machine learning-based tool for predicting the response of chronic pain patients to 4 different non-opioid pain treatment formulations. This tool is capitalizing on InSyBio’s unique machine learning technology to develop… Continue reading→
InSyBio DNA-seq has been launched allowing the discovery of genomic variants and their integration with other omics biomarkers
A new tool has been integrated in InSyBio Suite (InSyBio DNA-seq) which enables the fast and accurate pre-processing and analysis of DNA-sequencing data by non-bioinformatics experts with optimized pipelines. This tool includes the following functionalities: InSyBio’s CEO, Labros Digonis, stated that“Genomics is the area contributing more than 70% of the biomarkers used in clinical practice nowadays, being… Continue reading→
JSS forms strategic partnership with InSyBio to pioneer precision medicine innovation in clinical trials
In a bold approach to revolutionize a vital part of the pharmaceutical/nutraceutical industry and change the stagnant norm that is the clinical trial process, JSS Medical Research Inc. has strategically partnered with InSyBio, a leading bioinformatics company, to drive desperately needed transformation. With credit to Axios Investments Corporation for facilitating the partnership, InSyBio and JSS… Continue reading→
InSyBio Suite V2.6 has been launched offering a unique user experience and allowing exploration of the “dark matter” transcriptomics datasets
The new version of InSyBio Suite enables the fast and accurate analysis of omics data by non-bioinformatics experts empowered with novel techniques to explore the dark matter of the transcriptomics data. This new version: InSyBio Suite version 2.6 has been officially launched as of Friday November 15th 2019. The Chief Scientific Officer of InSyBio, Dr. Seferina Mavroudi, stated… Continue reading→
InSyBio showcasing its breakthrough technology in investment Community of Texas
ISyBio is showcasing as one of 7 prestigious companies during The International Accelerator’s Demo Day taking place October 22nd, 2019 at 4:30pm. As one of the leading companies in targeted biomarker discovery, InSyBio is revolutionizing both the medical and food/nutrition research fields. We drive innovation in both clinical trials and drug discovery through our proprietary analysis… Continue reading→